Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control

    March 2026 in “ Clinical Cosmetic and Investigational Dermatology ”
    M. Li, X. Wang, Jiehui Chen … Cuihong Lian
    Studysummary In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on dovepress.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients The Journal of Dermatology · 2025
    2. Vitiligo: Pathogenesis and New and Emerging Treatments International Journal of Molecular Sciences · 2023
    3. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    4. Alopecia Areata: What's New in the Epidemiology, Comorbidities, and Pathogenesis? Journal of Dermatological Science · 2023